AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company focused on developing proprietary botulinum neurotoxin therapeutics across aesthetic and neurological indications. The company entered public markets through a business combination with Primoris Acquisition Corp, a blank-check company that completed its initial public offering in 2021 and was sponsored by Primoris Capital Partners. AEON filed an 8-K with the Securities and Exchange Commission on August 12, 2026, reporting a disclosable corporate event under its ongoing public company obligations. Investors and analysts seeking comprehensive filing history, SPAC deal terms, and real-time monitoring of AEON and hundreds of other de-SPAC companies can access the full dataset by signing up at SpacDesk.